Sage Journals: Discover world-class research

Abstract

French

Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current therapies. In this brief review, we provide an update regarding the use of animal models to study schizophrenia in an attempt to understand its aetiology and develop novel therapeutic strategies. Tremendous progress has been made developing and validating rodent models that replicate the aetiologies, brain pathologies, and behavioural abnormalities associated with schizophrenia in humans. Here, models are grouped into 3 categories—developmental, drug induced, and genetic—to reflect the heterogeneous risk factors associated with schizophrenia. Each of these models is associated with varied but overlapping pathophysiology, endophenotypes, behavioural abnormalities, and cognitive impairments. Studying schizophrenia using multiple models will permit an understanding of the core features of the disease, thereby facilitating preclinical research aimed at the development and validation of better pharmacotherapies to alter the progression of schizophrenia or alleviate its debilitating symptoms.

Keywords

animal models schizophrenia dopamine glutamate 5-hydroxytryptamine (5-HT serotonin)

Schizophrenia is a severe mental illness with a lifetime prevalence of approximately 0.4% worldwide.¹ It can have devastating effects on patients and their caretakers and imposes enormous costs on health care systems. Schizophrenia is a heterogeneous disorder with positive symptoms (delusions, hallucinations, thought disorders), negative symptoms (anhedonia, avolition, social withdrawal, poverty of thought), and cognitive dysfunction. Although numerous antipsychotic drugs are available to mitigate the symptoms of schizophrenia, the response rate to these drugs is lower than desired, they are slow-acting, and they often produce serious adverse side effects. While the aetiology of schizophrenia is still poorly understood and the biochemical focus has been on dopamine and glutamate, multiple neurotransmitters and neuromodulators, including 5-hydroxytryptamine (5-HT), gamma-aminobutyric acid (GABA), glycine, D-serine, and neuroactive steroids, have been implicated in its pathophysiology.^2
–4 Based on the limited understanding of the biological origins of schizophrenia, there is a continued need for improved animal models of the disorder to better identify the origins of the varied symptoms and to develop and validate novel therapies. This article provides a brief overview of the models currently available and the complexities involved in attempting to develop and use such models.

In general, animal models of complex psychiatric disorders are valuable for studying the neurobiological bases of these disorders and for identifying new drug targets to provide more effective treatment in the future. Preclinical models allow for more rapid monitoring of disease progression than is possible in humans, permit invasive studies of structural and molecular changes across development of the disorder, and allow for relatively easy testing of potential therapeutic agents.⁵ However, neuropsychiatric disorders, including schizophrenia, include symptoms such as paranoid delusions and auditory hallucinations that are uniquely human and make interpretation of results obtained from animal models more difficult.⁶ For example, increased locomotor activity in response to psychotomimetic compounds such as amphetamine or noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonists is commonly used as an indication of positive symptoms in schizophrenia, a deficit in prepulse inhibition (PPI, where a weaker sound [prepulse] delivered prior to a stronger sound [pulse] inhibits the natural startle response to the second stimulus) is used as a proxy for sensorimotor gating problems, and changes in social interaction are used as an indicator of negative symptoms.⁵ While these tests provide relatively high-throughput evaluation of symptom progression or alleviation with treatment, their relationship to human symptoms can be questioned. More recently, the cognitive symptoms of the disorder have become a focus for research, an important consideration given the lack of effective treatments for these symptoms. The MATRICS initiative of the National Institute of Mental Health (NIMH) identified 7 cognitive domains specifically relevant for schizophrenia, and rodent tests have been proposed for each of these domains.⁷ The use of touchscreen-equipped operant conditioning chambers for studying cognition relevant to schizophrenia in rodents is increasingly common given the high face validity, ease of implementation, and high level of automation possible with these tasks.^8
–10 Touchscreen-equipped chambers include a touch-sensitive screen on one wall of the chamber that replaces the levers used in traditional operant conditioning tasks. During the tasks, rodents are required to touch specific areas of the screen according to a given rule to receive the food reward. The NIMH has also proposed the Research Domain Criteria (RDoC) approach for research into the biological underpinnings of behaviour, ultimately including psychopathology and mental disorders.^11,12 RDoC constructs have initially been divided into 5 domains (negative valence systems, positive valence systems, cognitive systems, social processes, and arousal and regulatory systems), all of which are affected in schizophrenia.¹³ Work integrating animal research related to mental illness, including schizophrenia, into the RDoC framework is ongoing.^14,15

As discussed in the editorial accompanying this issue, animal models are often sought that satisfy face, predictive, and construct validity. Most of the animal models currently used to study schizophrenia are developmental, drug induced, or genetic.⁵ The purpose of this article is to introduce readers of the Canadian Journal of Psychiatry to these strategies for studying schizophrenia in animals with a focus on recent findings. For an in-depth consideration of particular models, comprehensive articles regarding the various animal models of schizophrenia are available.^{5,16

–37} Table 1 summarizes common phenotypes associated with animal models of schizophrenia.

Table 1.

Common Phenotypes Associated with Animal Models of Schizophrenia Discussed in the Present Review.

Category	Measure	Description
Behavioural	Locomotor activity (positive symptoms)	Vigor of movement in response to a novel environment, stress, or pharmacological challenge (dopamine enhancers, NMDA receptor antagonists) is quantified.
	Sucrose preference (negative symptoms)	Preference for sweetened water over unsweetened water is measured.
	Social interaction (negative and cognitive symptoms)	Time spent in close proximity or direct contact with an unfamiliar or less familiar animal.
	Latent inhibition (attentional processes, cognitive symptoms)	A classical conditioning procedure whereby previously unreinforced stimuli are slower (less efficient) in generating a conditioned response than novel stimuli.
	Memory (cognitive symptoms)	Many tests have been validated to measure various aspects of working memory, declarative memory, recognition memory (visual, spatial, and olfactory domains), and conditioning.
	Reasoning and problem solving (cognitive symptoms)	Tests of behavioural flexibility in response to dynamic environments include set shifting and reversal learning.
	Prepulse inhibition (sensorimotor deficits)	A reduction in the acoustic startle response is typically observed if the startling stimulus is preceded close in time by a low-intensity prepulse.
	Anxiety-like behaviour	Patterns of exploration in environments such as the elevated plus maze, open field, or light-dark box.
Morphological/physiological	Enlarged lateral ventricles	Measurements of the volume of lateral ventricles using in vivo imaging techniques such as magnetic resonance imaging or postmortem analysis.
	Morphology of cortical, striatal, thalamic, and limbic areas	Includes measures of size/volume of brain areas, numbers of neurons, dendritic changes, and synaptic proteins.
	Myelination	Assessment of the extent of myelination, particularly of cortical axons.
	Glial cells	Changes in microglia, oligodendrocytes, and astrocytes are commonly studied.
	Integrity of extracellular matrix	Alterations in structures such as perineuronal nets and proteins, including reelin.
	Neurotransmitter-related alterations	Effects on dopamine, glutamate, serotonin (5-HT), GABA (notably parvalbumin-containing interneurons), glycine, D-serine, and neuroactive steroids.
	Patterns of brain activity	Neural activity, dopamine neuron, activity, and patterns of oscillatory activity are measured using in vitro and in vivo electrophysiology techniques.

While these measures relate to schizophrenia, it should be noted that none are exclusive for the disorder.¹⁶ See in-text citations for specific references to the measures listed.

GABA, gamma-aminobutyric acid; 5-HT, 5-hydroxytryptamine; NMDA, N-methyl-D-aspartate.

Developmental Models

Although the symptoms of schizophrenia typically appear in adolescence and early adulthood, there is now an extensive body of research linking schizophrenia to prenatal events such as obstetric complications or maternal infection during pregnancy.^38,39 Thus, developmental animal models of schizophrenia involve environmental manipulations and/or drug administration during the perinatal and/or early postnatal period. The offspring are then studied over the course of development.⁵ One of the first developmental preparations used to study schizophrenia involved neonatal lesions of the rat ventral hippocampus on postnatal day 7 via local injection of either the excitotoxin ibotenic acid or temporary inactivation via tetrodotoxin. Neonatal lesions, but not similar lesions conducted in early adulthood, lead to an array of abnormalities consistent with schizophrenia that emerge at various times after puberty,^40,41 similar to the typical onset of schizophrenia in late adolescence/early adulthood. Postnatal developmental manipulations involving administration of glutamate receptor agonists/antagonists, postweaning stress, or postweaning social isolation have also been used to model schizophrenia.^33,42
–44 Notably, postnatal social isolation results in behavioural changes in adulthood, including spontaneous locomotor hyperactivity, enhanced response to novelty, deficits in sensorimotor gating, cognitive impairment, and increased anxiety and aggression.⁵

The methylazomethanol (MAM) model involves prenatal administration of MAM into pregnant rats.^45,46 MAM is an antimitotic and antiproliferative agent that methylates DNA⁴⁷ and acts specifically on proliferation of neuroblasts without affecting glia or producing teratogenic effects in peripheral organs.⁴⁸ Administering MAM to pregnant rats results in neuroanatomical, electrophysiological, and behavioural changes in the offspring that depend on the gestational day (GD) of administration, with GD17 animals being the most commonly used in schizophrenia animal models.^49
–51 Changes in MAM offspring include decreased volume of the medial prefrontal cortex, increased volume of lateral and third ventricles, decreases in parvalbumin interneuron markers in limbic and cortical areas, increased dopamine neuron activity in the ventral tegmental area, increased locomotor response to amphetamine and MK-801, decreased social interaction, decreased PPI, impaired memory, and increased anxiety (reviewed in Moore et al.⁴⁵).

A second prenatal developmental strategy involves inducing maternal immune activation (MIA) in pregnant rodents with agents like the viral mimetic polyinosinic-polycytidylic acid (poly I: C) and studying the consequences for the offspring.^{52

–62} A rather large body of evidence indicates that the offspring of rodents and primates that have undergone MIA during pregnancy show anatomical, neurochemical, electrophysiological, and behavioural changes consistent with schizophrenia,^63

–69 as well as other neurodevelopmental disorders, including autism.⁷⁰ The maternal immune response appears critical for the effects of MIA on the offspring, with roles for maternal interleukin-6⁷¹ and interleukin-17a^72,73 identified. Recent work using the model has identified novel pathological changes in the offspring. For example, recent findings using this animal model implicate changes in parvalbumin interneurons and their associated perineuronal nets (extracellular matrix structures involved in structural and synaptic plasticity) in the prefrontal cortex (PFC) and hippocampal formation in cognitive deficits,^69,74,75 consistent with studies on postmortem tissue from individuals with schizophrenia.^74
–76 Using mice, Shin Yim and colleagues⁷⁷ showed that abnormalities in the primary somatosensory cortex underlie behavioural changes in the offspring following MIA.

Neurodevelopmental models permit investigations of the processes leading to the development of schizophrenia during the prodromal phase of the disease and potential development of prophylactic treatments to prevent the progression to psychosis.⁷⁸ Combined, recent work in the MAM, MIA, neonatal ventral hippocampal lesion, and postweaning stress and isolation models has shown that interventions conducted around the time of adolescence alleviate some of the brain and behaviour changes in the animals.^79

–85 These interventions include cognitive training, antipsychotic administration, antioxidant administration, and benzodiazepine administration. Moreover, these models allow unique opportunities to create “2-hit” models,⁸⁶ in which development is challenged during 2 critical periods (e.g., early brain development and then adolescence) in an effort to trigger a phenotype consistent with the development of schizophrenia later in life. While a single model is not sufficient to confirm efficacy for novel therapies, these well-validated neurodevelopmental models replicate many of the behavioural and neuroanatomical phenotypes of schizophrenia.^87,88 Each of these components of schizophrenia can then be targeted for pharmacotherapy independently with separate molecules or specifically designed multitarget drugs,⁸⁹ with the models providing accurate readouts of treatment efficacy.

Drug-Induced Models

The drugs used most frequently in animal models of schizophrenia are dopamine enhancers (e.g., amphetamine and apomorphine) and noncompetitive NMDA receptor antagonists (phencyclidine [PCP], ketamine, and MK-801). Amphetamine-induced psychosis in humans is well known and is proposed to result from the increased synaptic dopamine produced by this drug. Repeated, intermittent administration of amphetamine in rodents results in a persistent sensitization typified by exaggerated hyperactivity in response to an acute amphetamine challenge.⁹⁰ However, repeated amphetamine does not induce social interaction deficits (which are proposed to be equivalent to negative symptoms in schizophrenia)⁹¹ and appears to affect only some cognitive tasks related to PFC function while leaving hippocampal function relatively unaffected.⁹⁰ In summary, amphetamine induces psychotic-like changes but does not reliably produce negative or cognitive symptoms. In fact, some have proposed that treating selected patients with psychostimulants in an effort to improve negative symptoms is worth exploring.⁹²

Hypofunctioning of NMDA glutamate receptors in schizophrenia has received considerable interest in recent years. Hence, noncompetitive NMDA receptor antagonists (ketamine, PCP, MK-801) have been administered to rodents in the hope that they would provide useful animal models of schizophrenia.^93

–98 In humans, PCP induces hallucinations and delusions, progressive withdrawal and poverty of speech, and impaired cognitive performance.^99
–101 In rodents, acute PCP produces hyperlocomotion (proposed to have translational relevance to positive symptoms in humans), social withdrawal, impaired PPI, and cognitive deficits.^102
–104 Effects of new antipsychotic candidates such as positive allosteric modulators of metabotropic glutamate receptors, the tetrahydroprotoberberine govadine, and nitric oxide donors (e.g., sodium nitroprusside [SNP]) have been tested using acute MK-801–induced disruptions of touchscreen-based tasks relevant to schizophrenia. These novel treatments reverse deficits on tasks, including paired associates learning and trial-unique, delayed nonmatching-to-location tasks.^105

–108

NMDA receptor activation results in the production of neuronal nitric oxide (NO). Bujas-Bobanovic and colleagues¹⁰⁹ studied this relationship and found that PCP-induced effects in rats were blocked by the NO donor SNP. Hallak et al.¹¹⁰ translated these findings to patients and found that SNP, when administered by intravenous (IV) perfusion to patients with schizophrenia undergoing antipsychotic drug therapy, showed signs of improvement on scales measuring symptom severity within 4 hours. Notably, the improvements persisted for at least a week after a single dose of SNP. In healthy subjects, SNP was able to prevent psychogenic symptoms induced by ketamine.¹¹¹ Other studies by the same group in rats showed that a single dose of SNP prevented psychosis-like behaviour produced by ketamine¹¹² and that SNP treatment more consistently decreased ketamine-induced behaviours than other NO-related compounds.¹¹³ Thus, in these SNP studies, basic science research findings in animal models were translated to the clinical situation, then reverse translated back to animal models to further investigate mechanisms of action and other potential therapies. Such bidirectional translation is essential to developing new insights into the pathophysiology of schizophrenia and new avenues for treatment.

There has been a great deal of interest in the possible role of the amino acids glycine and D-serine, both coagonists at the NMDA receptor, in the aetiology and pharmacotherapy of schizophrenia. D-serine has a higher affinity than glycine for the serine glycine binding site on the GluN1 subunit of the NMDA receptor, and the focus of research has been more on D-serine in recent years. This emphasis will no doubt increase with recent withdrawal of glycine reuptake inhibitors from clinical trials.¹¹⁴ D-serine is formed from L-serine via serine racemase and catabolized by D-amino acid oxidase (DAO), and there is a great deal of interest in studies in rodents in which these enzymes are inhibited or induced by drugs or are knocked out, knocked down, or overexpressed in transgenic mice^115,116 in an effort to identify new drugs that may be effective antipsychotics. Genetic studies on D-serine will be discussed in a later section of this review.

Other models have used local injections of drugs into specific brain areas in an effort to mimic a known pathophysiology associated with schizophrenia. For example, alterations of parvalbumin-containing GABAergic interneuron number and function in the prefrontal cortex is strongly associated with schizophrenia¹¹⁷ and a number of animal models of the disorder.⁷⁴ Generally, these alterations are thought to result in reduced output of these neurons, thereby disturbing circuit function. In an effort to mimic this state in rodents, Tse and colleagues¹¹⁸ microinjected the GABA-A receptor antagonist bicuculline into rodent medial PFC and assessed cognition. Alterations in attentional processes, working memory, speed of processing, cognitive flexibility, emotion regulation, and locomotor activity consistent with a schizophrenia-like phenotype were observed.

Genetic Models

A genetic contribution to schizophrenia has long been a focus of study and the basis for several animal models. Numerous candidate genes have been associated with an increased risk of developing schizophrenia, and most of these genes relate to proteins relevant to neuronal plasticity, glutamatergic or dopaminergic function, and synaptogenesis.^118
–120 The largest genome-wide association study thus far, including data from 37,000 patients and 113,000 controls, was published in 2014.¹²¹ From this data set, 108 loci associated with schizophrenia were identified. Many of these genes have been used to generate animal models of schizophrenia, and new loci will allow for more models in mice. Notably, the identification of candidate genes is the first step in the generation of more sophisticated animal models of schizophrenia that incorporate the complex gene-by-environment interactions and gene-gene interactions that underlie the disease in humans.¹²² Several of the most established models based on genetic mutations are discussed below.

DISC1 (disrupted-in-schizophrenia 1) is a gene for DISC1, a synaptic protein expressed early in development and involved in pre- and postnatal development in neurons. DISC1 is considered a highly penetrant mutation and a risk factor for schizophrenia, although the genetic evidence for this claim has been debated.¹²³ Mice with inducible and/or partial loss of DISC1 function have brain morphology consistent with schizophrenia, including enlarged ventricles and reduced cortical thickness and brain volume.¹²⁴ Reduced immunoreactivity for parvalbumin, a marker of fast-spiking inhibitory interneurons, has also been observed in the medial PFC and hippocampus, consistent with postmortem studies in humans.¹²⁴ While hyperactivity and impairments in volitional behaviour have been observed, there is some controversy about the degree to which these animals show changes in PPI, locomotor activity, or differences in negative symptoms and cognitive abilities.^125

–128

22q11.2 deletion syndrome is a genetic syndrome resulting from a deletion on chromosome 22q11.2.¹²⁹ These deletions are associated with schizophrenia in humans and have been used to generate animal models of schizophrenia. It has been estimated that 22q11.2 deletions account for approximately 1% of cases of schizophrenia, with some studies suggesting as many as 22.6% of those with the deletions are diagnosed with schizophrenia or schizoaffective disorder.¹³⁰ The core symptoms, treatment response, cognitive deficits, and brain pathologies do not appear to differ in 22q11.2 deletions relative to those diagnosed with schizophrenia that do not have the deletions. The mouse model recapitulates the major neuroanatomical findings observed in 22q11.2 deletion carriers,¹³¹ with alterations in cortical and subcortical grey matter volumes, enlarged ventricles, and reduced spine size and dendritic complexity.¹³² Behavioural studies in mice with 22q11.2 microdeletions reveal deficits in PPI, fear conditioning, impaired spatial memory, and deficits in delayed nonmatching to place tasks.¹³³

Mutations in the genes for the cell adhesion molecule neuregulin 1 (NRG1) and its receptor ErbB4 also confer increased risk for schizophrenia.^134
–136 The NRG1 gene regulates expression of several isoforms of NRG1 that are involved in the development of the nervous system.¹³⁷ Homozygous knockout (KO) in mice is lethal, but viable heterozygous, hypomorphic conditioned KOs can modulate neuregulin-ErbB4 signaling.¹³⁸ These mice exhibit a behavioural phenotype with increased activity and exploration, and some reports noting working memory impairments in tests of spontaneous alternation^138,139 in NRG1 hypomorphic mice, but not Erb4 hypomorphs, show reduced PPI. Notably, NRG1 hypomorphs have significantly fewer functional NMDA receptors than wild-type mice and reduced dendritic spine density on pyramidal neurons of the hippocampus.

Dysbindin is a synaptic protein implicated in the regulation of exocytosis, vesicle biogenesis, and receptor trafficking processes involved in excitatory synaptic transmission.¹⁴⁰ A reduction in dysbindin expression affects NMDA receptor function and impairs working memory. Genetic variations in the gene encoding dysbindin impair cognition in humans and increase the risk for schizophrenia.^{140

–145} Moreover, dysbindin gene and protein expression are reduced in the hippocampus and PFC of schizophrenic patients. Dysbindin mutant mice show behaviours consistent with a schizophrenia-like phenotype, including hyperactivity, learning and memory deficits, and increased impulsive and compulsive behaviours. Moreover, the mutants have disrupted dopamine/D2 signaling and altered neuronal excitability.^146

–149

Reelin is involved in synaptic formation and plasticity, and reduced reelin messenger RNA (mRNA) and its corresponding protein have been reported in cerebellum, hippocampus, and frontal cortex of individuals with schizophrenia.⁵ Deletion of 1 allele encoding the reelin gene produces a heterozygous mutant mouse.¹⁵⁰ These mice have some schizophrenia-like pathology, including increased neuronal packing and reduced dendritic spine density in the frontal cortex and hippocampus.¹⁵¹ However, there is considerable controversy about the behavioural relevance of this model to schizophrenia, with variable findings in studies of social interaction, cognitive deficits, locomotor response, and PPI.⁵

Several genes showing up in association studies on schizophrenia are related to D-serine and include G72 (or DAP activator), DAO, and SRR (the gene for serum racemase).^115,116 Insertion of the human G72 gene in mice produces a model that mimics some behavioural and cognitive characteristics of schizophrenia.¹⁵² The genes for the enzymes involved in the formation (serine racemase) and catabolism (DAO) of D-serine can be manipulated relatively easily. Behavioural effects noted in mice in which serine racemase is inhibited (leading to decreased brain levels of D-serine) indicate that this situation results in behavioural effects corresponding to symptoms in humans with schizophrenia.¹⁵³ Conversely, genetic inactivation of DAO enhances extinction and reversal learning, suggestive of improvement of schizophrenia-like symptoms.¹⁵⁴ It should also be mentioned that research now indicates that D-serine has antidepressant properties and may be a biomarker for nonresponse to the antidepressant effects of ketamine.^155,156 Similarly, there is now extensive literature supporting GABAergic dysfunction in schizophrenia, including its interactions with dopamine and some neuroactive steroids.¹⁵⁷ With regard to animal models, deficiency of glutamate decarboxylase 67, the enzyme responsible for the conversion of glutamate to GABA in mice, results in a schizophrenia-like phenotype.¹⁵⁸

Sex Differences in Animal Models of Schizophrenia

There are clear sex differences with respect to age of onset, symptoms, and treatment/drug response in schizophrenia.¹⁵⁹ Sex differences also exist between males and females in animal models of schizophrenia.^160,161 These differences have been detected in both neurodevelopmental and genetic models of schizophrenia. Male- or female-specific deficits in PPI in offspring after prenatal PolyI: C have been reported, while deficits in both sexes were found in other studies.^162,163 Similarly, male-specific deficits have been reported in studies of fear conditioning,¹⁶⁴ set shifting,¹⁶⁵ and recognition memory,¹⁶⁶ while female-specific impairments have been reported in some, but not all, studies of spatial memory in polyI: C offspring.¹⁶⁷ In general, prefrontal cortex–dependent tasks, including latent inhibition,¹⁶⁸ PPI,¹⁶⁹ recognition memory,¹⁷⁰ and social behaviour,¹⁶² tend to be impaired to a greater extent in males than in females after MIA. These sex differences may parallel altered glutamate, aspartate and taurine concentrations, and parvalbumin-expressing inhibitory interneuron cell density in the prefrontal cortex of males but not females.¹⁶⁸ Interestingly, MIA with polyI: C may preferentially disrupt prefrontal cortex–dependent tasks, and these deficits may only manifest in adulthood, potentially due to the delayed maturation of prefrontal cortex or puberty-related hormonal changes.¹⁶⁰ However, statistical power (small group sizes per sex) and timing of polyI: C injection vary between studies and are important considerations in interpreting variable sex differences between polyI: C studies.¹⁶⁰ Sex differences have also been reported in a neurodevelopmental model using prenatal exposure to the bacterial toxin lipopolysaccharide (LPS). Wischhof et al.⁵⁷ reported that males, but not females, exhibited prolonged PPI deficits and impaired recognition memory. Interestingly, this study also reported deficient myelination in corticolimbic areas and reduced parvalbumin expression in the prefrontal cortex and hippocampus.

Overall, data on sex differences in genetic models of schizophrenia in the literature are variable and dependent on adequate sample size.¹⁶⁰ For example, studies investigating mutations in DISC1 have found that when mutations are induced postnatally, sex-specific behavioural differences are observed, with males exhibiting hyperactivity and altered social interaction while females are impaired in spatial memory.¹⁷⁰ Pre- and postnatal mutant expression results in increased aggression, altered social behaviour, and sensitivity to psychostimulant-induced locomotor hyperactivity in males and more depressive phenotypes in females.¹⁷¹ Male-specific increases in the ratio of excitatory to inhibitory synaptic activity in cortical pyramidal cells have also been reported in DISC1 mutants.¹⁷² Notably, mice with a naturally occurring mutation in DISCI show a similar phenotype to the inducible mutants, with male-specific hyperactivity. However, in these mutants, it was males that exhibited a depressive phenotype.¹⁷³ This variability is common in studies of DISC1, and approximately half of studies to date have reported no sex differences in cognitive tasks, depressive behaviours, or locomotor activity.¹⁵⁴

Variable sex differences have also been observed in other genetic models. Overall, cognitive impairments tend to be more severe in males in NRG1-ErbB4 mutants.¹⁶⁰ Male-specific deficits in spatial learning in the Morris water maze have also been reported,¹⁷⁴ but many studies lack statistical power to adequately detect sex differences.¹⁶⁰ As such, further investigation of sex-specific effects on mutations affecting NRG1-ErbB4 is required. While most studies including both sexes of reelin mutants lacked sufficiently large samples to differentiate between sexes, differences have been observed in studies of heterozygous reelin mutant mice with larger samples.¹⁷⁵ Adult male, but not female, heterozygous reelin mutant mice have enhanced locomotor response to MK-801¹⁷⁵ as well as deficits in social recognition memory. In virtually all cases, additional studies with adequate sample size for both sexes are required to better define sex differences in genetic models.

Glial Contributions to Schizophrenia

Glial cell dysfunction has been implicated in several animal models of schizophrenia.^176
–178 Activated microglia are an important part of the immune system and, by releasing proinflammatory cytokines, may contribute to symptoms seen in animal models based on immune reactions.^54
–56,179 Genetic mutation of the genes encoding CX3C chemokine receptor 1 (CX3CR1) fractalkine (CX3CL1) and its receptor (CX3CR1), which are concentrated in microglia and involved in immune cell trafficking to the central nervous system, induces a schizophrenia-like phenotype.^180,181 Similarly, genetic and proteomic studies in humans have suggested that abnormalities in the cytokines interleukin-6, interleukin-1B, interferon-Y, tumour necrosis factor α, and the major histocompatibility complex are associated with schizophrenia.^182

–186 Genetic and transcriptomic studies of S100B and glial fibrillary acid protein, both highly expressed in astrocytes, reveal altered expression in the plasma and brains of individuals with schizophrenia.^187,188 There is now also substantial evidence, using demyelination animal models such as rodents treated with cuprizone, that oligodendrocyte function and demyelination may also contribute to the symptoms of schizophrenia.^189,190 Oligodendrocyte-related genes are frequently identified as associated with schizophrenia in genetic, transcriptomic, and proteomic studies.¹⁹¹ Consistent with this, a genomic analysis of 10 publicly available gene sets identified a glial-oligodendrocyte pathway as significantly associated with schizophrenia, suggesting that these myelination abnormalities in schizophrenia are at least in part due to inherited factors.¹⁹² Thus, modeling of schizophrenia involves the integration of genetic factors across multiple cell types, neurodevelopmental processes, and complex gene-by-environment interactions.

Summary

Despite the complicated, heterogeneous aetiology of schizophrenia, which almost certainly includes contributions from both environmental and genetic factors, animal models have increased our knowledge of the brain pathology in schizophrenia. Moreover, these models allow for identification of pathways for pharmacotherapy and improved screening and validation of potential novel antipsychotics. With continued refinement of the models and our understanding of the pathophysiology of schizophrenia, the development of more rapidly acting therapies with reduced side effect profiles compared to the agents currently available is possible.

Footnotes

Acknowledgements

The authors are grateful for funding from the University of Alberta, the University of São Paulo, and the University of Saskatchewan. John G. Howland’s research in this area is supported by operating grants from the Canadian Institutes for Health Research (125984 and 153111). Ian R. Winship’s research in this area is supported by operating grants from the Canadian Institutes for Health Research (153111), the Natural Science and Engineering Research Council (RGPIN-2017-05380), the University Hospital Foundation, and Alberta Innovates Health Solutions.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Joao Paulo Maia-de-Oliveira, MD, PhD

References

Saha

Chant

Welham

. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.

Yang

Tsai

. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci. 2017;18(8). pii: E1689.

Salavati

Rajji

Price

. Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull. 2015;41(1):44–56.

Balu

Coyle

. The NMDA receptor ‘glycine modulatory site’ in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol. 2015;20:109–115.

Jones

Watson

Fone

. Animal models of schizophrenia. Br J Pharmacol. 2011;164(4):1162–1194.

Canetta

Kellendonk

. Can we use mice to study schizophrenia? Philos Trans R Soc Lond B Biol Sci. 2018;373(1742). pii: 20170032.

Young

Powell

Risbrough

. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009;122(2):150–202.

Hvoslef-Eide

Mar

Nilsson

. The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia. Psychopharmacology. 2015;232(21-22):3853–3872.

Bussey

Holmes

Lyon

. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology. 2012;62(3):1191–1203.

10.

Nithianantharajah

McKenchanie

Stewart

. Bridging the translational divide: identical cognitive touchscreen testing in mice and humans carrying mutations in a disease-relevant homologous gene. Sci Reports. 2015;5:14613.

11.

Cuthburt

Insel

. Toward the future of psychiatric diagnosis: the seven pillars of RdoC. BMC Med. 2013;11:126.

12.

Kozak

Cuthbert

. The NIMH research domain criteria initiative: background, issues, and pragmatics. Psychophysiology. 2016;53(3):286–297.

13.

Morris

Vaidyanathan

Cuthbert

. Changing the diagnostic concept of schizophrenia: the NIMH research domain criteria initiative. Nebraska Symposium Motivation. 2016;63:225–252.

14.

Kaffman

Krystal

. New frontiers in animal research of psychiatric illness. Methods Mol Biol. 2012;829:3–30.

15.

Young

Winstanley

Brady

. Research Domain Criteria versus DSM V: how does this debate affect attempts to model corticostriatal dysfunction in animals? Neurosci Biobehav Rev. 2017;76(Pt B):301–316.

16.

Nestler

Hyman

. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13(10):1161–1169.

17.

Macedo

Araujo

Sampaio

LRL

. Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review. Braz J Med Biol Res. 2012;45(3):179–186.

18.

Barnes

Der-Avakian

Markou

. Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia. Eur Neuropsychopharmacol. 2014;24(5):744–758.

19.

Bickel

Javitt

. Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res. 2009;204(2):352–362.

20.

Feifel

Shilling

. Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep. 2010;12(4):327–334.

21.

Flores

Morales-Medina

Diaz

. Neuronal and brain morphological changes in animal models of schizophrenia. Behav Brain Res. 2016;301:190–203.

22.

Geyer

Olivier

Joels

. From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends Pharmacol Sci. 2012;33(10):515–521.

23.

Green

Gabrielsson

Fone

KCF

. Translational neuropharmacology and the appropriate and effective use of animal models. Br J Pharmacol. 2011;164(4):1041–1043.

24.

Kannan

Sawa

Pletnikov

. Mouse models of gene-environment interactions in schizophrenia. Neurobiol Dis. 2013;57:5–11.

25.

Greek

Menache

. Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci. 2013;10(3):206–221.

26.

Lin

Sawa

Jaaro-Peled

. Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models. Neurobiol Dis. 2012;45(1):48–56.

27.

Mattei

Schweibold

Wolf

. Brain in flames—animal models of psychosis: utility and limitations. Neuropsychiatr Dis Treat. 2015;11:1313–1329.

28.

Miyamoto

Nitta

. Behavioral phenotypes for negative symptoms in animal models of schizophrenia. J Pharmacol Sci. 2014;126(4):310–320.

29.

Burrows

Hannan

. Cognitive endophenotypes, gene-environment interactions and experience-dependent plasticity in animal models of schizophrenia. Biol Psychol. 2016;116:82–89.

30.

O’Tuathaigh

Waddington

. Closing the translational gap between mutant mouse models and the clinical reality of psychotic illness. Neurosci Biobehav Rev. 2015;58:19–35.

31.

Powell

Miyakawa

. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry. 2006;59(12):1198–1207.

32.

Powell

. Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci. 2010;4:435–481.

33.

Puhl

Mintzopoulos

Jensen

. In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia. Neurobiol Dis. 2015;73:269–274.

34.

Severance

Prandovszky

Castiglione

. Gastroenterology issues in schizophrenia: why the gut matters. Curr Psychiatry Rep. 2015;17(5):27.

35.

Wischhof

Irrsack

Osorio

. Prenatal LPS-exposure—a neurodevelopmental rat model of schizophrenia—differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring. Prog NeuroPsychopharmacol Biol Psychiatry. 2015;57:17–30.

36.

Wong

Josselyn

. Caution when diagnosing your mouse with schizophrenia: the use and misuse of model animals for understanding psychiatric disorders. Biol Psychiatry. 2016;79(1):32–38.

37.

Yee

Singer

. A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res. 2013;354(1):221–246.

38.

Brown

Derkits

. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167(3):261–280.

39.

Brown

. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012;72(10):1272–1276.

40.

Becker

Grecksch

Bernstein

. Social behavior in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology. 1999;144(4):333–338.

41.

Tseng

Chambers

Lipska

. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res. 2009;204(2):295–305.

42.

Harris

Sharp

Gartlon

. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur J Neuorsci. 2003;18(6):1706–1710.

43.

Kjaerby

Hovelso

Dalby

. Phencyclidine administration during neurodevelopment alters network activity in prefrontal cortex and hippocampus in adult rats. J Neurophysiol. 2017;118(2):1002–1011.

44.

Howland

Hannesson

Phillips

. Delayed onset of prepulse inhibition deficits following kainic acid treatment on postnatal day 7 in rats. Eur J Neurosci. 2004;20(10):2639–2648.

45.

Moore

Jentsch

Ghajarnia

. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60(3):253–264.

46.

Lodge

Grace

. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res. 2009;204(2):306–312.

47.

Matsumot

Higa

. Studies on methylazoxymethanol aglycone of cycasin: methylation of nucleic acids in vitro. Biochem J. 1966;98(2):20C–22C.

48.

Cattabeni

DiLuca

. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev. 1997;77(1):199–215.

49.

Talamini

Ellenbroek

Koch

. Impaired sensory gating and attention in rats with developmental abnormalities of the mesocortex—implications for schizophrenia. Ann N Y Acad Sci. 2000;911:486–494.

50.

Gomes

Rincón-Cortés

Grace

. Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model. Neurosci Biobehav Rev. 2016;70:260–270.

51.

Modinos

Allen

Grace

. Translating the MAM model of psychosis to humans. Trends Neurosci. 2015;38(3):129–138.

52.

Feigenson

Kusnecov

Silverstein

. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72–93.

53.

Ibi

Yamada

. Therapeutic targets for neurodevelopmental disorders emerging from animal models with perinatal immune activation. Int J Mol Sci. 2015;16(12):28218–28229.

54.

Macedo

Araujo

Sampaio

. Animal models of prenatal immune challenge and their contribution to the study of schizophrenia: a systematic review. Braz J Med Biol Res. 2012;45(3):179–186.

55.

Muller

Weidinger

Leitner

. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.

56.

Reisinger

Khan

Kong

. The poly(I: C)–induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther. 2015;149:213–226.

57.

Wischhof

Irrsack

Osorio

58.

Fineberg

Ellman

. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry. 2013;73(10):951–966.

59.

Jenkins

. Perinatal complications and schizophrenia: involvement of the immune system. Front Neurosci. 2013;110:1–9.

60.

Feigenson

Kusnecov

Silverstein

. Inflammation and the two-hit hypothesis of schizophrenia. Neurosci Biobehav Rev. 2014;38:72–93.

61.

Möller

Swanepoel

Harvey

. Neurodevelopmental animal models reveal the convergent role of neurotransmitter systems, inflammation, and oxidative stress as biomarkers of schizophrenia: implications for novel drug development. ACS Chem Neurosci. 2015;6(7):987–1016.

62.

Müller

Weidinger

Leitner

. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.

63.

Meyer

. Prenatal poly (I: C) exposure and other developmental immune activation models in rodent systems. Biol Psychiatry. 2014;75:307–315.

64.

Dickerson

Overeem

Wolff

. Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Transl Psychiatry. 2014;4(7):e418.

65.

Howland

Cazakoff

Zhang

. Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neurosci. 2012;201:184–198.

66.

Piontkewitz

Arad

Weiner

. Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology. 2012;62(3):1273–1289.

67.

Zhang

Cazakoff

Thai

. Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats. Neuropharmacology. 2012;62(3):1299–1307.

68.

Machado

Whitaker

Smith

. Maternal immune activation in nonhuman primates alters social attention in juvenile offspring. Biol Psychiatry 2015;77(9):823–832.

69.

Paylor

Lins

Greba

. Developmental disruption of perineuronal nets in the medial prefrontal cortex after maternal immune activation. Sci Rep. 2016,6:37580.

70.

Careaga

Murai

Bauman

. Maternal immune activation and autism spectrum disorder: from rodents to nonhuman and human primates. Biol Psychiatry. 2017;81(5):391–401.

71.

Smith

Garbett

. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci. 2007;27(40):10695–10702.

72.

Choi

Yim

Wong

. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. Science. 2016;351(6276):933–939.

73.

Kim

Yim

. Maternal gut bacteria promote neurodevelopmental abnormalities in mouse offspring. Nature. 2017;549(7673):528–532.

74.

Steullet

Cabungcal

Coyle

. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry. 2017;22(7):936–943.

75.

Giovanoli

Weber

Meyer

. Single and combined effects of prenatal immune activation and peripubertal stress on parvalbumin and reelin expression in the hippocampal formation. Brain Behav Immunity. 2014;40:48–54.

76.

Careaqa

Murai

Bauman

. Maternal immune activation and autism spectrum disorder: from rodents to nonhuman and human primates. Biol Psychiatry. 2017;81(5):391–401.

77.

Shin Yim

Park

Berrios

. Reversing behavioural abnormalities in mice exposed to maternal inflammation. Nature. 2017;549(7673):482–487.

78.

Powell

Risbrough

Geyer

. Potential use of animal models to examine anti-psychotic prophylaxis for schizophrenia. Clin Neurosci Res. 2003;3:289–296.

79.

Pantazopoulos

Markota

Jaquet

. Aggrecan and chondroitin-6-sulfate abnormalities in schizophrenia and bipolar disorder: a postmortem study on the amygdala. Transl Psychiatry 2015;5(1):e496.

80.

Tseng

Chambers

Lipsla

. The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia. Behav Brain Res. 2009;204(2):295–305.

81.

Chambers

Moore

McEvoy

. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology. 1996;15(6):587–594.

82.

Gomes

Rincon-Cortes

Grace

. Adolescence as a period of vulnerability and intervention in schizophrenia: insights from the MAM model. Neurosci Biobehav Rev. 2016;70:260–270.

83.

Piontkewitz

Arad

Weiner

. Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology. 2012;62(3):1273–1289.

84.

Patterson

. Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res. 2009;204(2):313–331.

85.

Fone

KCF

Porkess

. Behavioural and neurochemical effects of post-weaning social isolation in rodents—relevance to developmental psychiatric disorders. Neurosci Biobehav Rev. 2008;32(6):1087–1101.

86.

Keshavan

Hogarty

. Brain maturational processes and delayed onset in schizophrenia. Psychopathology. 1999;11(3):525–543.

87.

Wilson

Terry

Jr . Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin Schizophr Relat Psychoses. 2010;4(2):124–137.

88.

Powell

. Models of neurodevelopmental abnormalities in schizophrenia. Curr Top Behav Neurosci. 2010;4:435–481.

89.

Gründer

Hippius

Carlsson

. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8(3):197–202.

90.

Featherstone

Rizos

Kapur

. A sensitizing regimen of amphetamine that disrupts attentional set-shifting does not disrupt working or long-term memory. Behav Brain Res. 2008;189(1):170–179.

91.

Sams-Dodd

. A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology. 1998;18(4):293–304.

92.

Lindenmayer

Nasrallah

Pucci

. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizoph Res. 2013;147(2-3):241–252.

93.

Grayson

Barnes

Markou

. Postnatal phencyclidine (PCP) as a neurodevelopmental animal model of schizophrenia pathophysiology and symptomatology: a review. Curr Top Behav Neurosci. 2016;29:403–428.

94.

Janhunen

Svard

Talpos

. The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacol (Berl). 2015;232(21-22):4059–4083.

95.

Jeevakumar

Driskill

Paine

. Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice. Behav Brain Res. 2015;282:165–175.

96.

Jeevakumar

Driskill

Paine

97.

Lodge

Mercier

. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–4276.

98.

Kocsis

Brown

McCarley

. Impact of ketamine on neuronal network dynamics, translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther. 2013;19(6):437–447.

99.

Luby

Cohen

Rosenbaum

. Study of a new schizophrenomimetic drug, sernyl. AMA Arch Neurol Psychiatry. 1959;81(3):363–369.

100.

Steinpreis

. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychoses. Behav Brain Res. 1996;74(1-2):45–55.

101.

Javitt

Zukin

. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–1308.

102.

Kalinichev

Robbins

Hartfield

. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;32(2):414–422.

103.

Sams-Dodd

. Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol. 1995;6(1):55–65.

104.

Mansbach

Geyer

. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology. 1989;2(4):299–308.

105.

Lins

Howland

. Effects of the metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on rats tested with the paired associates learning task in touchscreen-equipped operant conditioning chambers. Behav Brain Res. 2016;301:152–160.

106.

Lins

Phillips

Howland

. Effects of D- and L-govadine on the disruption of touchscreen object-location paired associates learning in rats by acute MK-801 treatment. Psychopharmacology. 2015;232(23):4371–4382.

107.

Lins

Marks

Phillips

. Dissociable effects of the d- and l- enantiomers of govadine on the disruption of prepulse inhibition by MK-801 and apomorphine in male Long-Evans rats. Psychopharmacology. 2017;234(7):1079–1091.

108.

Hurtubise

Marks

Davis

. MK-801–induced impairments on the trial-unique, delayed nonmatching-to-location task in rats: effects of acute sodium nitroprusside. Psychopharmacology. 2017;234(2):211–222.

109.

Bujas-Bobanovic

Bird

Robertson

. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol. 2000;130(5):1005–1012.

110.

Hallak

Maia-de-Oliveira

Abrao

. Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized double-blind, placebo-controlled trial. JAMA Psychiatry. 2013;70(7):668–676.

111.

Rezende

TMN

Maia-de-Oliveira

Kandratavicius

. Effects of sodium nitroprusside in the prevention of schizophrenia-like symptoms induced by ketamine—a translational double-blind study. Arch Clin Psychiatry. 2017;44(6):149–153.

112.

Maia-de-Oliveira

Lobao-Soares

Ramalho

. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week. Schizophr Res. 2015;162(1-3):211–215.

113.

Kandratavicius

Balista

Wolf

. Effects of nitric oxide–related compounds in the acute ketamine animal model of schizophrenia. BMC Neurosci. 2015;16:9.

114.

Thomas

Baker

Dursun

. Glycine reuptake inhibitors in the treatment of negative symptoms of schizophrenia. Bull Clin Psychopharmacol. 2014;24(3):195–200.

115.

Nunes

MacKenzie

Rossolatos

. D-serine and schizophrenia: an update. Expert Rev Neurotherapeutics. 2012;12(7):801–812.

116.

Labrie

Wong

Roder

. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology. 2012;62(3):1484–1503.

117.

Gonzalez-Burgos

Cho

Lewis

. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry. 2015;77(12):1031–1040.

118.

Tse

Piantadosi

Floresco

. Prefrontal cortical gamma-aminobutyric acid transmission and cognitive function: drawing links to schizophrenia from preclinical research. Biol Psychiatry. 2015;77(11):929–939.

119.

Harrison

Weinberger

. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2002;10(1):40–68.

120.

Farrell

Werge

Sklar

. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;20(5):555–562.

121.

Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014.6

122.

McOmish

Burrows

Hannan

. Identifying novel interventional strategies for psychiatric disorders: integrating genomics, ‘enviromics’ and gene-environment interactions in valid preclinical models. Br J Pharmacol. 2014;171(20):4719–4728.

123.

Sullivan

. Questions about DISC1 as a genetic risk factor for schizophrenia. Mol Psychiatry. 2013;18(10):1050–1052.

124.

Jaaro-Peled

Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res. 2009;179:75–86.

125.

Clapcote

Lipina

Millar

. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron. 2007;54(3):387–402.

126.

Hikida

Jaaro-Peled

Seshadr

. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA. 2007;104(36):14501–14506.

127.

Kvajo

McKellar

Arguello

. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA. 2008;105:7076–7081.

128.

Lipina

Zai

Hlousek

. Maternal immune activation during gestation interacts with Disc1 point mutation to exacerbate schizophrenia-related behaviours in mice. J Neurosci. 2013;33(18):7654–7666.

129.

Bassett

Chow

EWC

. Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Reports. 2008;10(2):148–157.

130.

Bassett

Chow

Husted

. Clinical features of 78 adults with 22q11 deletion syndrome. Am J Med Gen. 2005;138(4):307–313.

131.

Ellegood

Markx

Lerch

. Neuroanatomical phenotypes in a mouse model of the 22q11.2 microdeletion. Mol Psychiatry. 2014;19(1):99–107.

132.

Stark

Bagchi

. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet. 2008;40(6):751–760.

133.

Karayiorgou

Simon

, Gogos JA. 22q11.2 Microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci. 2010;11(6):402–416.

134.

O’Tuathaigh

O’Sullivan

Kinsella

. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygoud neuregulin-1 knockout mice. Neuroreport. 2006;17(1):79–83.

135.

Stefansson

Sigurdsson

Steinthorsdottir

. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–892.

136.

Karl

Duffy

Scimone

. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007;6(7):677–687.

137.

Engel

Snikeris

Jenner

. Neuregulin 1 prevents phencyclidine-induced behavioral impairments and disruptions to GABAergic signaling in mice. Int J Neuropsychopharmacol. 2015;18(7):pyu114.

138.

Mei

Xiong

. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9(6):437–452.

139.

Chen

Y-J

Johnson

Lieberman

. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci. 2008;28(27):6872–6883.

140.

Burdick

Lencz

Funke

. Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet. 2006;15(10):1563–1568.

141.

Fallgatter

Herrmann

Hohoff

. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology. 2006;31(9):2002–2010.

142.

Talbot

Eidem

Tinsley

. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004;113(9):1353–1363.

143.

Weickert

Rothmond

Hyde

. Reduced DTNBP1 (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizo Res. 2008;98(1-3):105–110.

144.

Weickert

Straub

McClintock

. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry. 2004;61(6):544–55.

145.

Tang

LeGros

Louneva

. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is recued in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet. 2009;18(20):3851–3863.

146.

Cox

Tucker

Tang

. Neurobehavioral abnormalities in the dysbindin-1 mutant, sandy, on a C57BL/6 genetic background. Genes Brain Behav. 2009;8(4):390–397.

147.

Papaleo

Yang

Garcia

. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviours via dopamine/D2 pathways. Mol Psychiatry. 2012;17(1):85–98.

148.

Carr

Jenkins

Weinberger

. Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior. Behav Brain Res. 2013;241:173–184.

149.

Karlsgodt

Robleto

Trantham-Davidson

. Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance. Biol Psychiatry. 2011;69(1):28–34.

150.

Liu

Pesold

Rodriguez

. Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc Natl Acad Sci USA. 2001;98(6):3477–3482.

151.

Kruger

Howell

Hebert

. Assessment of cognitive function in the heterozygous reeler mouse. Psychopharmacology (Berl). 2006;189(1):95–104.

152.

Otte

Bilkei-Gorzó

Filiou

. Behavioral changes in G72/G30 transgenic mice. Eur Neuropsychopharmacol. 2009;19(5):339–348.

153.

Labrie

Fukumura

Rastogi

. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet. 2009;18(17):3227–3243.

154.

Labrie

Duffy

Wang

. Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in mice. Learn Mem. 2008;16(1):28–37.

155.

Malkesman

Austin

Tragon

. Acute D-serine treatment produces antidepressant-like effects in rodents. Neuropsychopharmacology. 2012;15(8):1135–1148.

156.

Hashimoto

. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology. 2014;231(20):4081–4082.

157.

Wassef

Baker

Kochan

. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol. 2003;23(6):601–640.

158.

Fujihara

Miwa

Kakizaki

. Glutamate decarboxylase 67 deficiency in a subset of GABAergic neurons induces schizophrenia-related phenotypes. Neuropsychopharmacology. 2015;40(10):2475–2486.

159.

Goldstein

Cherkerzian

Tsuang

. Sex differences in the genetic risk for schizophrenia: history of the evidence for sex-specific and sex-dependent effects. Am J Med Genet B Neuropsychiatr Genet. 2013;162B(7):698–710.

160.

Hill

. Sex differences in animal models of schizophrenia shed light on the underlying pathopsychology. Neurosci Behav Rev. 2016;67:41–56.

161.

Kekesi

Petrovszki

Benedek

. Sex-specific alterations in behavioral and cognitive functions in a “three hit” animal model of schizophrenia. Behav Brain Res. 2015;284:85–93.

162.

O’Leary

Desbonnet

Clarke

. Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience. 2014;277:294–305.

163.

Ratnayake

Quinn

LaRosa

. Prenatal exposure to the viral mimetic poly I: C alters fetal brain cytokine expression and postnatal behavior. Dev Neurosci. 2014;36(2):83–94.

164.

Vorhees

Graham

Braun

. Prenatal immune challenge in rats: altered responses to dopaminergic and glutamatergic agents, prepulse inhibition of acoustic startle, and reduced route-based learning as a function of maternal body weight gain after prenatal exposure to poly IC. Synapse. 2012;66(8):725–737.

165.

Zhang

Cazakoff

Thai

. Prenatal exposure to a viral mimetic alters behavioural flexibility in male, but not female, rats. Neuropharmacology. 2012;62(3):1299–1307.

166.

Howland

Cazakoff

Zhang

. Altered object-in-place recognition memory, prepulse inhibition, and locomotor activity in the offspring of rats exposed to a viral mimetic during pregnancy. Neuroscience. 2012;201:184–198.

167.

O’Leary

Desbonnet

Clarke

. Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience. 2014;277:294–305.

168.

Nelson

Thur

Marsden

. Catecholaminergic depletion within the prelimbic medial prefrontal cortex enhances latent inhibition. Neuroscience. 2010;170(1):99–106.

169.

Hill

. Sex differences in animal models of schizophrenia shed light on the underlying pathophysiology. Neurosci Biobehav Rev. 2016;67:41–56.

170.

Pletnikov

Ayhan

Nikolskaia

. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry. 2008;13(2):173–186.

171.

Ayhan

Abazyan

Nomura

. Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry. 2011;16(3):293–306.

172.

Holley

Wang

Cepeda

. Frontal cortical synaptic communication is abnormal in Disc1 genetic mouse models of schizophrenia. Schizophr Res. 2013;146(1-3):264–272.

173.

Gómez-Sintes

Kvajo

Gogos

. Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders. Front Behav Neurosci. 2014;8:253.

174.

Golub

Germann

Lloyd

. Behavioral characteristics of a nervous system- specific erbB4 knock-out mouse. Behav Brain Res. 2004;153(1):159–170.

175.

van den Buuse

Halley

Hill

. Altered N-methyl-D-aspartate receptor function in reelin heterozygous mice: male-female differences and comparison with dopaminergic activity. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2):237–246.

176.

Xia

Abazyan

Jouroukhin

. Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia. Schizophrenia Res. 2016;176(1):72–82.

177.

Wang

Aleksic

Ozaki

. Glia-related genes and their contribution to schizophrenia. Psychiatry Clin Neurosci. 2015;69(8):448–461.

178.

Bilimoria

Stevens

. Microglia function during brain development: new insights from animal models. Brain Res. 2015;1617:7–17.

179.

Aricioglu

Ozkartal

Unal

. Neuroinflammation in schizophrenia: a critical review and the future. Bull Clin Psychopharmacol. 2016;26(4):429–437.

180.

Rogers

Morganti

Bachstetter

. CX#CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci. 2011;31(45):16241–16250.

181.

Reshef

Kreisel

Beroukhim

. Microglia and their CX3CR1 signaling are involved in hippocampal- but not olfactory bulb–related memory and neurogenesis. Brain Behav Immun. 2014;41:239–250.

182.

Fillman

Cloonan

Catts

. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18(2):206–214.

183.

Mondelli

Cattaneo

Murri

. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J Clin Psychiatry. 2011;72(12):1677–1684.

184.

Meisenzahl

Rujescu

Kirner

. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry. 2001;158(8):1316–1319.

185.

Paul-Samojedny

Owczarek

Suchanek

. Association study of interferon gamma (IFN-y) + 874T/A gene polymorphism in patients with paranoid schizophrenia. J Mol Neurosci. 2011;43(3):309–315.

186.

Miller

Buckley

Seabolt

. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–671.

187.

Katsel

Byne

Roussos

. Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology. 2011;36(6):1171–1177.

188.

Sugai

Kawamura

Iritani

. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci. 2004;1025:84–91.

189.

Chew

Fusar-Poli

Schmitz

. Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia. Dev Neurosci. 2013;35(2-3):102–129.

190.

. White matter abnormalities and animal models examining a putative role of altered white matter in schizophrenia. Schizophr Res Treat. 2011;2011:826976.

191.

Wang

Aleksic

Ozaki

. Glia-related genes and their contribution to schizophrenia. Psychiatry Clin Neurosci. 2015;69(8):448–461.

192.

Duncan

Holmans

Lee

. Pathway analyses implicate glial cells in schizophrenia. PLoS One. 2014;9(2):e89441.

An Overview of Animal Models Related to Schizophrenia

Abstract

Keywords

Developmental Models

Drug-Induced Models

Genetic Models

Sex Differences in Animal Models of Schizophrenia

Glial Contributions to Schizophrenia

Summary

Footnotes

Acknowledgements

Declaration of Conflicting Interests

Funding

ORCID iD

References